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BACKGROUND. Gene regulated in breast cancer 1 (GREB1) is a novel estrogen-regulated
gene shown to play a pivotal role in hormone-stimulated breast cancer growth. GREB1 is
expressed in the prostate and its putative promoter contains potential androgen receptor (AR)
response elements.
METHODS. We investigated the effects of androgens on GREB1 expression and its role in
androgen-dependent prostate cancer growth.
RESULTS. Real-time PCR demonstrated high level GREB1 expression in benign prostatic
hypertrophy (BPH), localized prostate cancer (L-PCa), and hormone refractory prostate cancer
(HR-PCa). Androgen treatment of AR-positive prostate cancer cells induced dose-dependent
GREB1 expression, which was blocked by anti-androgens. AR binding to the GREB1 promoter
was confirmed by chromatin immunoprecipitation (ChIP) assays. Suppression of GREB1 by
RNA interference blocked androgen-stimulated LNCaP cell proliferation.
CONCLUSIONS. GREB1 is expressed in proliferating prostatic tissue and prostate cancer, is
regulated by androgens, and suppression of GREB1 blocks androgen-induced growth
suggesting GREB1 may be critically involved in prostate cancer proliferation. Prostate
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INTRODUCTION
Prostate cancer is the most common lethal malig-
nancy affecting men in the United States with an
estimated 240,000 new cases and 30,000 deaths per year
[1]. Androgenic hormones play a critical role in normal
prostate function and have been shown to play a
significant role in the both the initiation and progres-
sion of prostate cancer [2–4]. They mediate their
physiological effects by binding to a specific steroid
receptor, androgen receptor (AR), which is the key
regulator of androgen signaling. Hormone bound AR
forms homodimers which bind to androgen response
elements (AREs) in gene regulatory regions and recruit
coactivators which activate the transcription of andro-
gen-regulated genes. The growth, development, and
function of the prostate are controlled by androgens
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through the complex pattern of genes regulated in this
way, as is the proliferation of prostate tumors. Many
androgen-regulated genes have the potential to reg-
ulate proliferation; however, the genes that are criti-
cally required for growth remain elusive. Identification
of the key mediators of hormone-stimulated cancer
growth could lead to new potential targets and more
effective therapies.
Nearly all prostate cancers are initially ARþ/
androgen dependent and respond to anti-androgen
therapy; however, almost all eventually develop an
androgen-independent phenotype [4]. Deregulation of
the AR signaling pathway plays a major role in the
progression of prostate cancer to an androgen-inde-
pendent/hormone refractory state and studies have
shown that AR and most AR-regulated genes are
constitutively expressed in the majority of androgen-
independent tumors [5,6]. Thus, it seems likely that the
key genes responsible for androgen-stimulated tumor
cell proliferation become constitutively upregulated in
androgen-independent disease and present attractive
therapeutic targets.
In an attempt to identify key genes responsible for
estrogen-stimulated proliferation in breast cancer, our
laboratory used Affymetrix Genechip1 microarrays to
identify genes, the regulation of which mirrored the
proliferative response of breast cancer cells to estrogens
and anti-estrogens. Using this approach, we identified
gene regulated in breast cancer 1 (GREB1), a gene
previously known to be estrogen-regulated, and
showed by small interfering RNA (siRNA)-mediated
knockdown and other strategies that it is a key regu-
lator of estrogen-stimulated proliferation [7]. Analysis
of the 10 kb region 50 of the GREB1 transcriptional start
site demonstrated that it contains multiple putative
hormone response elements including those for estro-
gen receptor (ER), progesterone receptor (PR), gluco-
corticoid receptor (GR), and AR. This led us to
hypothesize that GREB1 might be an androgen-regu-
lated gene, and that it could play an important role in
androgen-regulated proliferation in prostate cancer.
MATERIALSANDMETHODS
Cell Lines,Culture Conditions, andGrowthAssays
Testosterone (T), dihydrotestosterone (DHT), 17b-
estradiol (E2), flutamide (Flu), nilutamide (Nil), and
cyproterone acetate (Cyp-A) were purchased from
Sigma-Aldrich, Inc. (St. Louis, MO). Bicalutamide
(Casodex1) and methyltrienolone (R1881) were kindly
provided by Dr. Diane M. Robins (University of
Michigan, Ann Arbor, MI). Letrozole (Femara1) was
kindly provided by Dr. David A. Flockhart (Indiana
University, Indianapolis, IN). Cell culture medium was
purchased from Biosource International, Inc. (Camar-
illo, CA) and bovine serums from Valley Biomedical,
Inc. (Winchester, VA). All tumor cell lines were
originally purchased from American Type Culture
Collection (Rockville, MD) except the VCaP cell line
which was obtained from the Pienta laboratory. Cell
lines were maintained at 378C in a 5% CO2 atmosphere
in minimal essential medium (IMEM) supplemented
with 10% fetal bovine serum (FBS). For assays in
defined hormone conditions, cells were washed and
grown in steroid-depleted media (phenol red-free
IMEM supplemented with 10% charcoal stripped calf
bovine serum (CCS)) as described previously [7]. For
growth assays, cells were plated in steroid-depleted
media at 5 103 cells/well in 96-well plates (Falcon,
Lincoln Park, NJ) and cultured for 3 days before
treating with vehicle control (ethanol 0.1%), E2, andro-
gens, and the steroid antagonists. Relative cell number
was determined using the crystal violet assay as
described previously [8].
Clinical Prostate Specimens
Three benign prostatic hypertrophy (BPH), five
localized prostate cancers (L-PCa), and seven hormone
refractory prostate cancers (HR-PCa) (primary and
metastatic) specimens were obtained from the Univer-
sity of Michigan Rapid Autopsy Tissue Procurement
Program. Samples were collected with Institutional
Review Board approval as described previously [9].
Clinical and pathology data were obtained as described
previously [9].
RNAExtraction
Total RNA was isolated using TRIzol1 Reagent
(Invitrogen Corp., Carlsbad, CA) according to the
manufacture’s instructions. Yield and quality were
determined by spectrophotometry (Beckman DU1 640,
Beckman Coulter, Inc., Fullerton, CA) and using a
Bioanalyzer RNA 6000 Nano chip (Agilent Technolo-
gies, Palo Alto, CA). All samples were stored at 808C.
Real-Time PCR
GREB1 mRNA expression was measured using a
semi-quantitative real-time PCR assay as described
previously [7]. Briefly, total RNA (1 mg) was reverse
transcribed using Reverse Transcription System (Pro-
mega, Madison, WI) and cDNA amplified in a 25 ml
reaction containing Platinum Supermix UDG (Invitro-
gen Corp.), 250 nM of each primer (forward 50-CAA
AGA ATA ACC TGT TGG CCC TGC-30 and reverse 50-
GAC ATG CCT GCG CTC TCA TAC TTA-30–Inte-
grated DNA Technologies, Inc., Coralville, IA), 10 nM
fluorescein (BioRad, Inc., Hercules, CA), and Syber
Green. Reactions were performed using an iCycler
Thermal Cycler (BioRad, Inc.). To control for RNA
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quality and quantity, GREB1 expression was normal-
ized to the housekeeping genes 36B4 (forward 50-GTG
TTC GAC AAT GGC AGC AT-30 and reverse 50-GAC
ACC CTC CAG GAA GCG A-30) and GAPDH (forward
50-GAA GGT GAA GGT CGG AGT C-30 and reverse
50-GAA GAT GGT GAT GGG ATT TC-30) as described
previously [7]. To evaluate the quality of product
of real-time PCR assays, melt curve analyses were
performed after each assay. Relative expression was
determined using the DDCT method with either
GAPDH or 36B4 as the reference genes [10].
Chromatin Immunoprecipitation (ChIP)Assay
LNCaP cells grown in steroid-depleted media were
treated for 1 and 2 hr with 10 nM DHT or vehicle
control. ChIP assays were performed using the Quick-
ChIP Chromatin Immunoprecipitation Kit (IMGENEX
Corp., San Diego, CA) according to manufacture’s
instructions with slight modifications. Chromatin was
cross-linked using a 1% formaldehyde solution for
5 min at 378C and sheared using the ChIP-IT Enzymatic
Shearing Kit (Active Motif, Carlsbad, CA) for 10 min.
The samples were immunoprecipitated overnight at
48C with 5 mg/ml of a polyclonal androgen-receptor
antibody (catalog #IMG-3238, IMGENEX Corp.), a
goat IgG (catalog #I5256, Sigma-Aldrich, Inc.) or a no
antibody control. Washes, elution, and overnight
reversal of cross-links were carried out according to
the manufacturer’s instructions. The DNA was purified
using a QIAquick PCR Purification Kit (Qiagen, Inc.,
Valencia, CA) and PCR performed using an iCycler
Thermal Cycler (BioRad, Inc.). Primers (forward
sequence 50-GGG AGG GAT GGA GGA CAA GAA
G-30 and reverse 50-GGC CAA CCC TCA CTC TAA
CCC C-30) flanking the putative ARE from position
3371 to 3353 were used in three-step amplification
reaction with an annealing temperature of 608C.
GREB1mRNASuppressionUsing siRNA
Four synthetic siRNA duplexes were designed using
standard criteria and purchased from Dharmacon, Inc.
(Lafayette, CO). A non-silencing siRNA duplex, with
no homology to any known sequence was used as
a control (catalog #D-001206-09, Dharmacon, Inc.).
LNCaP cells were cultured for 4 days in steroid-free
medium as described above, then transfected with
100 nM siRNA specific to GREB1 or control siRNA
using OligofectamineTM reagent in serum-free Opti-
MEM-1 medium (Invitrogen Corp.) according to the
manufacture’s instructions for 4 hr then medium
replaced with phenol red-free IMEM supplemented
with 10% CCS. After 24 hr, the cells were treated with
R1881 (109 M) then assayed for GREB1 mRNA at 24 hr
and growth at 4 days.
RESULTS
Previous studies from our laboratory have shown
that GREB1, an estrogen-regulated gene, is critically
involved in hormone-dependent breast cancer growth.
Sequence analysis of the putative GREB1 promoter
region suggested that GREB1 might also be regulated
by androgens and could play a similar key role in the
regulation of prostate tumors by androgens. In order to
evaluate this possibility, we first determined whether
GREB1 is expressed at significant levels in prostatic
tissue and in prostate tumors. RNA was prepared from
three benign prostatic hypertrophy, five localized
prostate cancer, and seven hormone refractory prostate
cancer samples. GREB1 message levels were measured
by real-time RT-PCR and the results are shown in
Figure 1. GREB1 mRNA levels are expressed relative to
the level in MCF-7 breast cancer cells which we have
previously shown by real-time PCR and Northern blot
analysis to express high levels of GREB1. Data are
plotted on a log scale and all samples were found to
express high levels of GREB1 consistent with the
possibility that the gene plays an important role in
prostate biology. GREB1 was also shown to be expres-
sed in the AR-positive prostate cancer cell line LNCaP,
but not in the AR-negative line PC-3. This association
with AR expression in cell lines was confirmed with
additional AR-positive and negative lines (VCaP and
DU-145, respectively; not shown), again suggesting
that GREB1 might be an androgen-regulated gene.
In order to investigate the regulation of GREB1
expression by androgens, LNCaP cells were cultured in
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Fig. 1. ClinicalexpressionofGREB1.RNAwasisolatedfromthree
benignprostatichypertrophy(BPH), fivelocalizedprostate cancers
(L-PCa), and sevenhormonerefractoryprostate cancers (HR-PCa)
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steroid-depleted conditions then treated with the
synthetic androgen R1881, or the natural AR ligands
T and DHT (1012 to 108 M). Representative data
generated with LNCaP cells are shown in Figure 2a,
with data plotted as the fold induction (mean and
standard deviation of triplicate determinations) over
vehicle control treated cells. All three androgens
induced GREB1 mRNA in a dose-dependent manner
with 108 M R1881, T, and DHT inducing GREB1 by
7.3 1.2, 9.8 1.2, and 15.6 3.6, respectively. Treat-
ment with androgens produced very similar results in
the VCaP cell line as shown in Figure 2b. We next tested
whether the induction of GREB1 by androgens could be
reversed with anti-androgens. In VCaP cells (Fig. 2c),
1 nM T induced GREB1 (7.0 0.4-fold) over control and
was reversed by 1 mM treatment of the anti-androgens
bicalutamide (2.6 0.3-fold), flutamide (3.6 0.9-fold),
nilutamide (1.9 0.4), and cyproterone acetate (3.6
0.9-fold). Bicalutamide, flutamide, and nilutamide
alone (1 uM) did not affect expression of GREB1 while
cyproterone acetate (1 uM) alone did induce GREB1
(4.2 0.9-fold) consistent with its known partial ago-
nistic effects on the AR. Chromatin immunoprecipita-
tion assay confirmed ligand-dependent AR binding to
the putative ARE from position 3371 to 3353 as
shown in Figure 3. LNCaP cells were grown in steroid-
depleted conditions then treated with 10 nM DHT for
1 and 2 hr. Immunoprecipitated DNA was readily
detected after 2 hr treatment while none was observed
in the goat IgG controls and only trace amounts detec-
ted in the vehicle controls suggesting some residual
androgens may have been present.
The LNCaP cells are androgen sensitive and their
growth stimulated above basal levels when treated
with androgens [11]. In our previous work, we showed
that the estrogen-dependent proliferation of breast
cancer cells could be suppressed by knocking down the
expression of GREB1 with siRNA, suggesting that the
gene plays a key role in estrogen-stimulated growth [7].
We were, therefore, interested in determining whether
GREB1 might play a similar role in androgen-stimu-
lated proliferation. LNCaP cells were cultured for
4 days in steroid hormone-free medium, then trans-
fected with GREB1 siRNA duplexes. After 24 hr, the
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Fig. 2. Dose-dependent induction of GREB1by androgens pros-
tate cancer cell lines is reversible with anti-androgens. LNCaP (a)
andVCaP (b) cellswere cultured for 3days in steroid-depletedcon-
ditions, treated with a dose range (1012 to108 M) of R1881,T, and
DHT.After24hr,cellularRNAwasextractedandassayedforGREB1
mRNA expression using real-time PCR.The effects of T (109 M)
were reversedwhenVCaPcellswere cotreated (106 M)with anti-
androgens CS, Flu,Nil, and Cyp-A (c).The results are shown as the
fold normalized expression (mean and standard deviation of tripli-
catedeterminations)over vehicle control treatedcells.
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cells were treated with 108 M R1881, and then assayed
for GREB1 expression and growth after 24 hr and
4 days, respectively. As shown in Figure 4, treatment
with 108 M R1881 induced GREB1 mRNA 16.4
5.7-fold and cellular growth by 136 7%. The control
siRNA had no effect on either the basal or R1881-
induced GREB1 mRNA levels and growth. In contrast,
the siRNAs targeting GREB1 blocked R1881-induced
GREB1 mRNA induction by 59.5% and suppressed
cellular growth to basal levels. These results suggest
that GREB1 plays an important role in androgen-
induced prostate cancer growth.
Previous studies have shown that LNCaP cells
express a mutated form of AR which can be activated
by estrogen [12]. The cells also express the b-form of the
ER [13]. We wished to determine whether treatment
with estrogen could also induce GREB1 in these cells.
LNCaP cells were cultured in steroid-depleted condi-
tions then treated with 109 M E2 and assayed for
GREB1 induction (Fig. 5a) and cellular growth (Fig. 5b).
E2 treatment induced GREB1 mRNA by 11.6 5.4-fold
and cellular growth by 202 8%. A 100-fold molar
excess of the anti-androgen bicalutamide or the anti-
estrogen ICI 182,780 partially blocked the effect of
E2 while the combination of antagonist completely
blocked the growth (118 12%) and GREB1 induction
(0.5 0.7-fold) observed in these cells. No effect was
seen with either bicalutamide or ICI 182,780 treatment
in the absence of E2 (data not shown). These results
show that both AR and ERb can mediate GREB1
induction in these cells and that GREB1 induction
correlates with cellular growth.
To further study the induction of GREB1 expression
by androgen and estrogen receptors, studies were done
with a panel of cells of various AR and ER receptor
status, using a variety of androgens and estrogens. The
ERa/ARþ breast cancer cell line MDA-MB-453 [14]
showed a threefold induction of GREB1 when treated
with 108 M DHT. In contrast, neither R1881, T nor
DHT treatment induced GREB1 in the ERaþ/AR BT-
474 and T47D breast cancer cell lines despite robust
induction by E2 (data not shown). Interestingly, we did
observe a dose-dependent induction of GREB1 in the
ERaþ/ARþMCF-7 breast cancer cell line when treated
with T but not with R1881 at concentrations as high as
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Fig. 3. Ligand-dependent AR binding to a putative ARE in the
GREB1promoter.LNCaPcellsweretreatedfor1and2hrwitheither
vehicle control or 10 nM DHT and ChIP assays performed as
described in the Materials and Methods section.The putative ARE
sequence was immunoprecipitated by an anti-AR antibody in
extracts from cells treated for 2 hr DHT. No signal was detected
in the control antibody immunoprecipitates while control PCR
reactions show robust amplification of the target sequence in
inputDNA.
Fig. 4. SuppressionofGREB1by siRNAblocks androgen-induced
growth.LNCaP cells were cultured in steroid-depleted conditions,
transfected with a pool of synthetic siRNA duplexes specific to
GREB1oracontrolsiRNA,andafter24hr treatedwithR1881(108M).
a: After 24 hr, cellular RNAwas extracted and assayed for GREB1
mRNAusingreal-timeRT-PCRandtheresultsshownasthefoldnor-
malizedexpression(meanandstandarddeviationof triplicatedeter-
minations) over vehicle control treated cells. b: Cellular growth
(% over control) was assayed on day 4 using crystal violet staining
andshownas themeanandstandarderrorof sixreplicate samples.
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108 M. GREB1 is highly induced by E2 treatment in
MCF-7 cells, and so we speculated that the observed
GREB1 induction by T was due to aromatization of T to
E2. To evaluate this possibility MCF-7 cells were treated
with a range of concentrations of T (1011 to 108 M)
and of the aromatase inhibitor letrozole (107 M). As
shown in Figure 6, letrozole completely blocks T-
mediated GREB1 mRNA induction (Fig. 6a) and
growth (Fig. 6b) in MCF-7 cells while having no effect
on E2-induced GREB1 mRNA (Fig. 6c) or growth
(Fig. 6d) in these cells. In addition, the effects of T were
completely reversed by treating with the anti-estrogen
ICI 182,780 but not with the anti-androgen bicaluta-
mide (data not shown). These results demonstrate that
T-induced GREB1 mRNA and growth in MCF-7 cells is
due to aromatization of T to E2.
DISCUSSION
Previously, we used DNA microarrays to identify
estrogen-regulated genes in human breast cancer and
found GREB1 to be one of only three genes induced by
E2 that were common to three ERaþ breast cancer cell
lines. Our detailed in vitro and in vivo characterization
of GREB1 demonstrated that it plays an important role
in hormone-induced breast cancer growth [7]. In the
current study, we show that GREB1 is regulated by
the AR as well as ERb and is required for androgen-
induced prostate cancer growth. These results are not
entirely surprising given the similarities between
breast and prostate cancer including: high rates of
hormone dependency, growth suppression with hor-
mone blockade, and progression to hormone indepen-
dency [2,15]. Although comparisons between ER- and
AR-regulated genes have been made before, this is the
first study to show that a critical regulator of hormone-
induced growth is share between breast and prostate
cancer.
Ligand binding to AR induces a conformational
change resulting in homodimer formation. These
homodimers bind to AREs in gene promoter regions.
There are numerous variants of the ARE consensus
sequences found in multiple AR-regulated genes;
however, they typically contain a core sequence of
GGTACA nnn TGTTCT and require at least three out of
four guanines (underlined) [16]. The putative GREB1
promoter region contains three potential AREs with
one from position 3371 to 3353 having very similar
sequence homology to the core sequence (gtGGTGCA
tgg TGTTCAtc). ChIP analyses confirmed direct bind-
ing of AR to this ARE in a ligand-dependent manner.
These data clearly show that GREB1 is an androgen-
regulated gene as it is induced in a dose-dependent
manner by multiple androgens and this is reversible
with anti-androgens. Full analysis of the GREB1
promoter region is needed to confirm the identity and
function of the AREs in the GREB1 promoter region.
In addition to androgens, 17b-estradiol induced
GREB1 in the LNCaP cell line and this was partially
reversed with anti-androgens and anti-estrogens and is
completely reversed with a combination treatment. The
LNCaP cell line was originally described as an ARþ/
androgen-sensitive prostate cancer cell line established
from a metastatic lesion [11]. Subsequent studies show
that they express a mutated form of the androgen
receptor that can bind and be activated by E2 as well
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Fig. 5. Estrogen-induced GREB1 expression in the ARþ/ERbþ
LNCaP prostate cancer cell line.Cells were cultured for 3 days in
steroid-depleted conditions before treatmentwith E2 (109 M), E2
plus bicalutamide (107 M), E2 plus ICI182,780 (107 M) or E2 plus a
combination of bicalutamide (Cas), and ICI 182,780 (ICI). a: After
24 hr, cellular RNAwas extracted and assayed for GREB1mRNA
usingreal-timeRT-PCRandtheresultsshownas thefoldnormalized
expression (mean and standard deviation of triplicate determina-
tions) over vehicle control treated cells.b: Cellular growth (% over
control)wasassayedonday4usingcrystalviolet stainingandshown
as themeanandstandarderrorof10replicate samples.
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ERb but not ERa [12,13]. We conclude that the
induction of GREB1 by E2 in these cells is through both
the mutated AR and ERb. Further support for this is
that testosterone’s effects on GREB1 expression could
only be partially blocked by anti-androgens suggesting
aromatization and activation of ERb. Although the
induction of GREB1 through the androgen receptor
pathway is a completely novel finding, the induction of
GREB1 by ERb has been shown previously. Stossi et al.
investigated the differential gene regulation of ERa
versus ERb by transfecting an ER-osteosarcoma cell
lines with either isoform and identified genes using
DNA microarray [17]. A search of the data presented in
their study demonstrates that GREB1 is induced both
by ERa and ERb consistent with both our previous
results concerning ERa [7] and our current results
with ERb. We also noted that GREB1 promoter region
contains progesterone receptor response elements.
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Fig. 6. Testosterone induces GREB1 expression in the ERaþ/AR MCF-7 breast cancer cell line. Cells were cultured for 3 days in
steroid-depletedconditionsbefore treatmentwithadoserangeofT (1011to108M)either aloneor in thepresenceof a fixeddoseofletrozole
(107 M). Shown as controls are the effects of letrozole (L) alone and in combinationwith E2 (109 M). a andc: After 24 hr, cellular RNAwas
extractedandassayed forGREB1mRNAusingreal-timeRT-PCRand theresults shownas the foldnormalizedexpression (meanand standard
deviation of triplicate determinations) over vehicle control treatedcells.b andd: Cellular growth (%over control)was assayedonday 4 using
crystalviolet stainingandshownas themeanandstandarderrorof fivereplicate samples.
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Although we did not test for progesterone receptor
responsivity in this study, analysis of data presented by
Jacobsen et al. using DNA microarrays and the human
breast cancer cell line T47D engineered to express either
PRa or PRb under an inducible promoter showed that
GREB1 is induced by PRb but not PRa in a classical
ligand-dependent manner [18].
In all, it appears that GREB1 is regulated by multiple
hormone nuclear receptors including at least ERa, ERb,
PRb, and AR as shown in this study. The significance of
this is not yet understood; however, it does suggest that
GREB1 plays an important role in hormone responsive
tissue. GREB1 was originally discovered in the human
brain [19]. Its gene spans roughly 108 kb of the short
arm of chromosome 12 (p25.1). It has three known
transcripts with the longest coding for a putative 1949-
aa protein with at least four transmembrane domains
and a N-myristoylation domain (http://www.ncbi.
nlm.nih.gov/IEB/Research/Acembly). Ghosh et al.
were the first to show that GREB1 is an early response
gene directly regulated by ER and suggested that it
plays an important role in hormone-responsive tissues
and cancer [20]. The cellular functional role of GREB1 is
not yet known and is an area of active research. The
results of this study are significant in that they provide
an additional avenue for which to study the effects of
GREB1 in hormone-stimulated cancer growth.
In this study, we found GREB1 to be highly
expressed uniformly in both benign and malignant
prostate cells and it is interesting to note that GREB1
was highly expressed in seven hormone refractory
prostate samples taken from men who had bilateral
orchiectomy and/or pharmacological blockade [9].
We did not observe any correlations between GREB1
expression and the pathology data available for these
samples including Gleason score and AR status. This is
probably due to the small number of samples analyzed
and this important question is being addressed in
future studies. However, it is interesting to note that
GREB1 is expressed in AR-negative samples which
may be due to ERb activity in these cells. We therefore
speculate that high expression of GREB1 plays a role in
prostate cancer progression. Although we only exam-
ined a small number of clinical samples (n¼ 15), it
appears that upregulation of GREB1 is a common
occurrence in proliferating prostate tissues and suggest
that it plays a role in prostate cancer growth. In support
of this theory is the fact that deregulation of the
androgen signaling pathway plays a major role in
hormone refractory prostate cancer and that many of
the genes required for androgen growth are upregu-
lated [4]. Further evidence suggesting an important
role for GREB1 in prostate cancer growth include our
results using siRNA in which ‘‘knockdown’’ of the
expression of GREB1 in the LNCaP cells led to the
suppression of hormone-induced growth. Further-
more, these results are constant with what is known
are about the differences between breast cancer and
prostate cancers. Many breast cancers become hormone
independent by upregulating alternative growth sig-
naling pathways while prostate cancer tends to dereg-
ulate the AR signaling pathway in that the cells are no
longer dependent upon hormone but are still depen-
dent on the androgen signal transduction pathway.
In conclusion, our results show that GREB1 is an
androgen-regulated gene, it is expressed in hormone
refractory prostate cancer and suppression of GREB1
blocks androgen-induced growth. These results have
important implications in that they suggest GREB1
may play an important role in prostate cancer growth
and may be a prognostic as well as predictive marker
of androgen responsiveness. Furthermore, our results
suggest that GREB1 may be a target for prostate
cancer treatment and suggested that the effects of
GREB1 are not confined only to the breast but it also
plays an important role in other hormone-dependent
malignancies.
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